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Abstract
Background: Postoperative adhesions occur when fibrous strands of internal scar tissue bind anatomical structures to 
one another. The most common cause of intra-abdominal adhesions is previous intra-abdominal surgical intervention. 
Up to 74% of intestinal obstructions are caused by post surgical adhesions. Although a variety of methods and agents 
have been investigated to prevent post surgical adhesions, the problem of peritoneal adhesions remains largely 
unsolved. Materials serving as an adhesion barrier are much needed.
Methods/Design: This is a prospective, randomised, controlled, patient blinded and observer blinded, single centre 
phase I-II trial, which evaluates the safety of A-Part® Gel as an adhesion prophylaxis after major abdominal wall surgery, 
in comparison to an untreated control group. 60 patients undergoing an elective median laparotomy without prior 
abdominal surgery are randomly allocated into two groups of a 1:1- ratio. Safety parameter and primary endpoint of 
the study is the occurrence of wound healing impairment or peritonitis within 28 (+10) days after surgery. The frequency 
of anastomotic leakage within 28 days after operation, occurrence of adverse and serious adverse events during hospital stay 
up to 3 months and the rate of adhesions along the scar within 3 months are defined as secondary endpoints. After 
hospital discharge the investigator will examine the enrolled patients at 28 (+10) days and 3 months (±14 days) after surgery.
Discussion: This trial aims to assess, whether the intra-peritoneal application of A-Part® Gel is safe and efficacious in the 
prevention of post-surgical adhesions after median laparotomy, in comparison to untreated controls.
Trial registration: NCT00646412
Background
Post surgical adhesions are quite common, i.e. they can
affect up to 93% of patients undergoing abdominal sur-
gery [1,2]. Adhesions are internal scars developing after
trauma and involving the injured tissue and the perito-
neum [3]. The magnitude of the problems caused by
adhesions was highlighted by several studies [4-7].
Depending on the location and the structure of the adhe-
sion serious complications may be caused thereby, such
as large and small bowel obstruction. Pelvic adhesions are
associated with infertility in 15-20% of cases [8]. A num-
ber of products that help to reduce or to prevent tissue
adhesion are marketed [2]. Barrier materials in various
forms such as films, viscous gels and intra-peritoneal
solutions have been used clinically for the prevention of
surgical adhesions. However, these materials have had
limited success, and no treatment is adopted so far as a
standard therapy [9].
Rationale
Several materials and methods have been tested for the
prevention of post surgical adhesions, but the problem is
still unsolved [10-12]. The most established method in
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adhesion prevention is to apply a barrier between the
wounded surfaces. Barrier materials should be easy to
apply and should remain in place for several days to allow
serosal re-epithalization and should be resorbed after-
wards and excreted without systemic reactions or inap-
propriate accumulation. Materials should be non-
inflammatory and non-reactive and should not interfere
with the healing processes of sutures, anastomoses or the
incision.
Purpose
A-Part® Gel [13] a bioresorbable transparent gel com-
posed of polyvinylalcohol (PVA) and carboxymethylcellu-
lose (CMC) was developed to meet these features
mentioned above. Both components PVA and CMC are
already used for various biomedical applications [14-17].
The established use of PVA and CMC has confirmed
their good biocompatibility [10,18-25]. Material charac-
teristics and preclinical data of animal studies have estab-
lished the promising properties of A-Part® Gel as a new
measure against post surgical adhesions [26,27]. There-
fore this prospective, randomised, controlled, patient and
observer blinded trial was designed as a first evaluation of
the safety of A-Part® Gel as an adhesion prophylaxis after
abdominal surgery in comparison to a non treated con-
trol group in man.
Methods/Design
Objectives of the study
The aim of this study is a first assessment of the safety of
A-Part® Gel applied as an adhesion prophylaxis after
major abdominal surgery, by specific observation of two
major complications of abdominal surgery; wound heal-
ing impairment or peritonitis; in comparison to a non
treated control group (primary objective) within 28 (+10)
days after surgery (for definition see table 1). The inci-
dence of adverse events and serious adverse events occur-
ring 3 months postoperatively, with special attention to
anastomotic leakage, between the two treatment groups,
will be used to further consider the safety of A-Part® Gel.
To explore the efficacy of A-Part® Gel in reducing post-
surgical adhesions, ultrasound examination will be per-
formed up to 3 months postoperatively (secondary objec-
tives).
The incidence of adhesions between the visceral organs
and the abdominal wall will be diagnosed by ultrasound
examination using a linear-array transducer. The scar of
the abdominal incision will be divided into equal parts of
2,5 cm, starting 2 cm from the cranial beginning of the
scar. At each assessment point spontaneous visceral slide
(produced by regular and deep respiration motion) will
be examined using ultrasound scanning. Reduced move-
ment following respiration will count as restricted vis-
ceral slide, i.e. adhesions. The total number of assessment
Table 1: Diagnostic criteria of complications
Complication Diagnostic criteria/Definition
Impaired wound healing
a)Delayed wound healing • Necrosis of wound edge
• Dehiscence
b) Development of surgical site 
infection
• Purulent secretion from the 
wound
• Germ organism isolated from 
an aseptically obtained culture 
of fluid or tissue from superficial 
incision
• Local signs of infection or 
systemic signs (fever, 
leukocytosis, rising CRP) without 
other plausible causes (e.g. 
pneumonia, urinary tract 
infection)
• Diagnosis of an abscess in deep 
soft tissue (an abscess in deep 
soft tissue is defined as 
microbiological verification of 
suspect specimen which is 
generally taken by means of 
ultrasonic puncture)
Peritonitis • fever, leukocytosis, abdominal 
pain, muscular defense, absence 
of bowel sounds, metabolic 
disturbances or severe 
hypotension with multiple organ 
failure (MOF)
Diagnosis confirmed by:
▪ Fluid collection by puncture or 
drainage
▪ Sonography
▪ Computed tomography
▪ Re-Intervention/Revision
Anastomosis leakage • Fever, abdominal pain, 
metabolic disturbances, intra-
abdominal abscesses, or sepsis 
with multiple organ failure 
(MOF)
Diagnosis confirmed by:
▪ Fluid collection by puncture or 
drainage
▪ Sonography
▪ Computed tomography
▪ Colonic contrast enema (water 
soluble contrast medium)
▪ Re-Intervention/RevisionLang et al. BMC Surgery 2010, 10:20
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points and the number of assessment points with adhe-
sions will be documented.
Primary endpoint
- Occurrence of wound healing impairment or post-
operative peritonitis within 28 (+10) days after sur-
gery.
Impaired wound healing is defined as delayed wound
healing or the development of surgical site infection.
Delayed wound healing has to be diagnosed if at least
one of the following criteria is fulfilled:
- Necroses of wound edges occur.
- Primary or secondary dehiscence occurs (primary 
dehiscence is defined as retreating of wound edges 
immediately after surgery; secondary dehiscence is 
defined as retreating of wound edges after start of the 
wound healing.
Surgical site infection and postoperative peritonitis has
be assumed as present, if one or more of the criteria
which are shown in table 1 are fulfilled.
Secondary endpoints
- Occurrence of anastomosis leakage within 28 (+10) 
days after surgery.
- Occurrence of Adverse Events (AE) and Serious 
Adverse Events (SAE) during the postoperative hospi-
tal stay and up to 3 months after surgery.
- Adhesion rates along the scar after 14 days, 28 (+10) 
days and 3 months (±14 days) days examined by ultra-
sound.
For the definition of anastomosis leakage please see
table 1. Assessment of adhesion development will be
done by ultrasound assessment. Sigel et al. described a
technique for non-invasive ultrasound examination to
detect and map abdominal adhesions. The findings that
identify abdominal wall adhesions are based on the pres-
ence or restriction of ultrasonically observed movement
of abdominal viscera in reference to abdominal wall.
Design
This is a prospective, randomised, controlled, double-
blinded, single centre study. Patients will be blinded as
well as the evaluating physician conducting the ultra-
sound examination. In case of a non sufficient recruit-
ment this study can be expanded into a multicentre trial.
Patients enrolled in the trial will be randomly allocated
either to the treatment group receiving A-Part® Gel or to
the untreated control group (for inclusion and exclusion
criteria see table 2). Randomisation will take place during
the operation. Initially there will be a staggering of the
treatment of the patients, so that during the early phase
of the study there is a one-by one exposure of patients to
A-Part® Gel. Both groups consist of 30 patients. After dis-
charge from the hospital the investigator will examine the
patients at 28 days (+10) and after 3 months (±14 days)
after surgery (figure 1).
Eligibility
Detailed inclusion and exclusion criteria are specified in
table 2. Patients are screened consecutively for eligibility
in the participating centre after approval of the study pro-
tocol by the local ethics committee of the Ludwig-Maxi-
milians-University (LMU), Munich, Germany. A contract
has been signed by Aesculap AG and the participating
centre for correct conduction of the trial according to
Good Clinical Practice. The participating surgeons per-
forming the intervention have been instructed by detailed
manuals.
Consent
The participating centre recruits trial patients from its
patients who are scheduled for an elective primary
Table 2: Eligibility Criteria
Inclusion criteria Exclusion criteria
• Patients of both sexes 
undergoing a primary elective 
median abdominal incision
• Patients with a known history 
of adhesion or peritonitis
• Age equal or greater than 18 
years
• Patients with a known 
sensitivity to polyvinylalcohol or 
carboxy-methylcellulose
• Written informed consent • Simultaneous participation in 
another clinical trial with 
interfering end-points
• Expected incison length ≥15 cm • Emergency surgery
• Expected survival time more 
than 12 months
• Patients with peritoneal 
carcinosis or peritoneal dialysis
• For female adults of 
reproductive potential: negative 
pregnancy test at visit 1 and 
sufficient contraception from 
time of written consent up to at 
least 4 months
• Patients with systemic 
immunsuppression (e.g. 
hydrocortisone >50 mg per 
daily, other immunsuppressants 
like Azathropin, 
Mycophenolatmofetil, 
Ciclosporin, Everolimus, 
Methotrexat ect.), 
chemotherapy or radiotherapy 
within the last 2 weeks prior 
surgery
• Patients with ascites >200 ml
• ASA > 3
• Patients with intra-abdominal 
abscess or other intra-
abdominal infection
• Renal impairment (Creatinine 
>1.3 mg/ml)
• Pregnant or breast-feeding 
women
• Lack of compliance
• Surgical procedures or patients 
which require insertion more 
than 2 intra abdominal drainsLang et al. BMC Surgery 2010, 10:20
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median abdominal incision with a expected length of ≥15
cm. All patients who seem to fit to the in- and exclusion
criteria will be asked whether they are willing to partici-
pate in the trial and they will be informed about the pur-
pose of the trial, the operation modalities, data
management, and their possibilities and risks. Interested
patients will be screened according to inclusion and
exclusion criteria and included into the trial after written
Informed Consent has been obtained from the patient.
Randomization
Block randomisation with randomly varying block sizes
and a ratio 1:1 to the two treatment arms will be used in
order to provide treatment groups of approximately equal
sizes. The block length will be documented separately
and will not be disclosed to the investigators. Randomisa-
tion code was generated by the statistician of the Clinical
Trials Centre (ZKS), Freiburg, Germany. To guarantee
concealment of the randomisation, it will be performed
using sealed opaque envelopes which were produced by
the ZKS and are kept at the study centre. Randomisation
will take place before abdominal wall closure. If there is
an explicit need to unblind during the follow up, the ran-
domisation envelopes can be used to unblind the patient.
Intervention
After the surgical procedure, the abdominal incision is
closed from the caudal and cranial end up to the middle
with a monofilament suture loop by using the continuous
suture technique. Up to 3 cm of the incision will be left
open in the middle of the incision. A-Part® Gel is pre-
pared and brought under the incision through the open
part in the middle. A-Part® gel syringe is placed to one
end of the incision. The A-Part® Gel is applied along the
partly sutured incision while pressing out slowly the vis-
cous gel onto the abdominal wall. This procedure is
repeated on the other half of the incision, and when the
syringe is taken out from the open middle part of the inci-
sion. Thereafter the abdominal incision is completely
closed according to the INSECT suture technique [28]
and the skin closure is performed with staples. It is rec-
ommended to use 10 ml of A-Part® Gel for covering 10
cm of incision. The A-Part® Gel is only applied by a
trained surgeon.
Study Device
A-Part® Gel is a sterile, absorbable, translucent adhesion
barrier composed of two unmodified water soluble bio-
compatible polymers: polyvinyl alcohol (PVA) and car-
boxymethylcellulose (CMC) [13,26]. Both components
PVA and CMC are already used for various biomedical
applications [10,16,17,22-25]. PVA is used in drug coat-
ing, contact lenses, tendon repair or artificial articular
cartilage [14,15]. CMC is used as an additive in tablets,
suspensions and creams. PVA is biologically inert and is
not degraded in mammal metabolism [29,30]. As a water
soluble polymer, PVA is mainly secreted by the kidneys,
only small amounts are excreted via faeces. CMC is a cel-
l u l o s e  d e r i v a t i v e  t h a t  i s  a l r e a d y  b e e n  u s e d  a s  b a r r i e r
m a t e r i a l  f o r  a d h e s i o n  p r o t e c t i o n  w i t h  g o o d  r e s u l t s
regarding efficacy and biocompatibility [10,22-25].
A-Part® Gel does not promote bacterial growth. A-Part®
Gel is indicated for use in patients undergoing abdominal
or pelvic surgery. A-Part® Gel is intended to reduce the
incidence, extent and severity of post-operative adhesions
between the abdominal wall and the underlying viscera
such as omentum, small bowel, bladder and stomach and
between the uterus and surrounding tissues such as tubes
and ovaries, large bowel and bladder. A-Part® Gel serves
as a temporary absorbable barrier separating the parietal
and visceral peritoneal tissue surfaces immediately after
surgery. A-Part® Gel acts as a physical barrier for adhesio-
genic tissue while the normal tissue repair takes place
Figure 1 Flow chart of treatment schedule. (1) Daily documenta-
tion until day 7 has to be done in the patient chart. CRF documentation 
will be done on day 1, 4, ±1 and 7 + 1 after surgery. Adverse events 
have to be documented as soon as they occur. (2) Has to be done daily 
with respective documentation in the patient file. (3) CRF documenta-
tion will be done on these days. (4) Generally if the patient is dis-
charged before day 7, all documentation required until the day of 
discharge (e.g. day 1, 4, etc.) has to be completed together with the 
discharge page (visit 3). However if discharge is on day 1, 4 + 1 or 7 + 1 
the documentation of the respective day (day1, 4 or 7) can be omitted 
(with the exception of the header which has to be filled in); only the 
discharge page (visit 3) needs to be filled in instead.Lang et al. BMC Surgery 2010, 10:20
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[26]. After placement on the tissue A-Part® Gel immedi-
ately attaches to the surface; A-Part® Gel is elastic, soft
and translucent [26]. A-Part® Gel is absorbed and under-
goes renal excretion within approx. 6 weeks [18].
Statistical consideration and sample size estimation
The aim of this study is a first assessment of the safety of
the application of A-Part® Gel as an adhesion prophylaxis
after major abdominal surgery as compared to control.
Sample size considerations are not based on statistical
calculations, but on the feasibility of recruitment. It is
planned to randomise 60 patients between A-Part® Gel
and control, because this is expected to be feasible within
six months from a single centre. This phase I study is con-
ducted as a first application of A-Part® Gel in man, and its
aim is to receive first safety data as compared to control.
The power considerations are based on the specific
observation of two major complications of abdominal
surgery "occurrence of wound healing impairment or
postoperative peritonitis within 28 (+10) days after sur-
gery" as a primary combined endpoint. It is assumed that
without application of the A-Part® Gel wound healing
impairment will occur with a probability of about 5-10%
and postoperative peritonitis will occur with a probability
of about 2-5% [31-33]. This leads to the assumption that
the combined endpoint will occur in the control group
with a probability of about 10-15%. It is the aim of the
study to show that the application of A-Part® Gel does not
lead to an unacceptable increase in the probability of
occurrence of the combined endpoint i.e the non-inferi-
ority of A-Part Gel® as compared to the control. Under
the assumption that the application of A-Part® Gel does
not increase the probability of the combined endpoint,
this study can show at one-sided significance level α = 5%
with a power of 80% that the absolute difference of the
event probabilities between both treatment groups is not
larger than 20-25% [34].
The two-sided 90%-confidence interval for the absolute
difference (A-Part® Gel minus control) of probability of
occurrence of the primary endpoint will be calculated. If
the upper bound of this confidence interval is below 0.25,
the hypothesis that the difference is 0.25 or larger will be
rejected. Adverse event incidences, wound healing
impairment, postoperative peritonitis, adhesion and
complication rates will be calculated with two-sided 90%
confidence intervals.
The safety analyses will be conducted in the safety pop-
ulation, including all randomized patients with group
assignment by treatment received. All analyses will be
done with the Statistical Analysis System (SAS).
No interim analysis is planned for this trial.
Clinical site and safety aspects
Clinical sites are selected according to their experience in
abdominal surgery, their clinical research experience, to
the number of eligible patients operated in the indicated
intervention per year and to their willingness to adhere to
clinical trial protocol. The participating centre is men-
tioned at the end of this paper.
The term "adverse event" covers any sign, symptom,
syndrome, illness that appear or worsen in a patient dur-
ing the period of observation in the clinical trial and that
may impair the well-being of the subject. The term also
covers laboratory findings of other diagnostic procedures
that are considered to be clinically relevant.
A "serious adverse event" is any event occurring at any
time during the period of observation that results in
death, is immediately life - threatening, requires or pro-
longs hospitalization, results in persistent or significant
disability and incapacity.
All SAEs are reported on a SAE report form and must
be sent by fax within 24 hours to the sponsor. The spon-
sor will notify the competent authorities, ethics commit-
tees and all other potential investigators about the SAEs
in line with applicable regulatory requirements.
Analysis of safety related data performed with respect
to:
- Frequency of SAEs
- Frequency of SAEs stratified by severity
- Frequency of SAEs stratified by causality.
Trial organization, quality control, registration and ethical 
aspects
The trial is initiated and sponsored by B|Braun Aesculap
and conducted by Aesculap AG in cooperation with the
Clinical Trials Centre (ZKS) in Freiburg, Germany. The
Clinical Trials Centre (ZKS) in Freiburg is responsible for
biometry, data base and project management. Monitor-
ing is done by an authorized, qualified, representative
person of Conventis AG who will visit the investigational
site at regular intervals to verify adherence to the proto-
col and legal requirements, perform source data verifica-
tion and assist the investigator in his related activities.
The sponsors role is limited to supplying the participat-
ing centre with the medical device and surgical support.
The sponsor is not involved in the data base manage-
ment. He has taken out an insurance policy to cover all
patients taken part in the trial.
The trial is coordinated by the Clinical Trials Centre
(ZKS) in cooperation with B|Braun Aesculap. Aesculap
AG has registered the trial on 13th November 2008 at the
clinical trials register (Identifier Number NCT00646412,
http://www.clinicaltrial.gov). Before the start of the trial
the independent ethics committee of the Ludwig-Maxi-
milians-University (LMU) of Munich gave their approval
on 3rd April 2008. The trial is performed according to theLang et al. BMC Surgery 2010, 10:20
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Declaration of Helsinki in its current German version, the
national medical device law and the guidelines for Good
Clinical Practice (GCP).
Data management and quality assurance
Data documentation will be performed on study-specific
case report form (CRF) consisting of 3-layer NCR paper,
which form a front end to the database. SAS software will
be used to review the data for completeness, consistency
and plausibility.
The clinical data base includes all information until 3
months post-operatively and will be closed after the 3
months follow-up visit of the last patient randomised into
the trial.
Current status and duration of the trial
The study protocol for the trial was completed on 13th
March 2008. After completion of the contract the study
was initiated on 9th  July 2008. One centre recruited
patients with the goal of 60 patients. After receiving the
positive ethics approval the first patient was randomized
on 28th July 2008. The recruitment was completed in
December 2009.
Discussion
Adhesions between visceral organs and the abdominal
wall are frequent sequelae of abdominal or pelvic surgery,
causing complications such as small bowel obstruction or
infertility [2,8,23]. Safe, efficient and easily to apply bar-
rier measures are still missing. Hyaluronic acid car-
boxymethylcellulose films, oxidized regenerated cellulose
and extended polytetrafluoroethylene film have been
used to prevent adhesions after surgical trauma [2]. The
use of a PVA membrane gave quite promising results
clearly better than other commercially available products
[26]. Membranes are not applicable in every surgical site.
Therefore a gel or a liquid solution is preferred in the pre-
vention of post surgical adhesions.
Anti-adhesion barriers basically fall under two main
categories: macromolecular solutions (crystalloids, poly-
saccharide, hyaluronic acid, fibrin, polyethylene glycol,
phospholipids) and mechanical devices (oxidized-regen-
erated cellulose, hyaluronic acid-carboxycellulose,
expanded polytetrafluoroethylene and autologous trans-
plants).
Crystalloid solutions are proposed to work by hydro-
floatation to separate raw peritoneal surfaces. But they
have a negative effect on post-operative adhesions [35],
because the volume of the applied crystalloids are
absorbed very rapidly [36]. By hydro-floatation and sili-
conization of intra-abdominal structures with polysac-
charide such as Dextran solutions a physiological
separation occurs between peritoneal surfaces. Data of
Dextran solution used as a barrier are discussed contro-
versial. There are studies showing good anti-adhesive
results but other studies failed to demonstrate any clinical
improvement and instead showed severe side effects such
as edema, ascites and coagulopathy [37,38].
Carboxymethylcellulose (CMC) is a derviate of cellu-
lose and works by separating raw surfaces and allowing
independent healing of traumatized peritoneal surfaces
[39,40]. CMC showed a good anti-adhesive effect in
experimental models but not in clinical trials. CMC in
membranes together with hyaluronic acid and CMC
membranes with polyethylene oxide and calcium chlo-
ride have also been reported as effective anti-adhesive
agents in clinical trials [41].
Oxidized regenerated cellulose (ORC) is another bar-
rier used for the prevention of adhesions [42]. When
applied to raw peritoneal surface, it gels within 8 h [43].
Experimental and clinical models reported good preven-
tive results by forming a barrier which physically sepa-
rates the adjacent raw peritoneal surfaces. However poor
results were noted in the presence of blood and probably
also at coexisting infections [44]. ORC is not widely used
in general surgery today.
The experimental effects of a glucose polymer have
been promising, reducing adhesions without obvious side
effects [45,46]. In a RCT it was shown that this polymer
reduces the incidence of adhesions and that its applica-
tion is safe and easy [46]. However, a Meta-analysis report
on pelvic adhesion, has not recommended this polymer
for the prevention of intra-abdominal adhesions [47].
Hyaluronic acid (HA) is a naturally occurring gly-
cosamin which is biocompatible, non immunogenic and
bioabsorbable, therefore it seems to be well suited as an
anti-adhesive agent [48]. Compounds consisting of HA
act as a barrier because they coat serosal surfaces and
provide a certain degree of protection from serosal desic-
cation and other types of injury. But they have also been
shown to have an anti-inflammatory effect [49-51]. The
most popular product on the market is Seprafilm®, a com-
bination of HA and CMC. Seprafilm® reduces adhesive
formation, but it is very expensive [13]. Its use increases
the risk of anastomotic deshiscence, the formation of
abscess [23] and inflammatory reaction [52].
In a previous randomized controlled trial the safety and
efficacy of another anti- adhesive agent, Intergel® was
evaluated in colorectal surgery [53]. Intergel® is a
hyaluronic based gel which is cross-linked with carboxy-
late groups by chelation with ferric (Fe3+) ions. The aim of
the study was to reduce the occurrence of intestinal
obstructions due to abdominal surgery using Intergel®.
Patients who received Intergel® showed a high incidence
of anastomotic dehiscence and a prolonged postoperative
ileus in comparison to the control group treated only
with distilled water. Furthermore, wound infections were
observed more often in the Intergel® group. Due to thisLang et al. BMC Surgery 2010, 10:20
http://www.biomedcentral.com/1471-2482/10/20
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high incidence of adverse effects in the Intergel® treated
group the study was prematurely terminated. The authors
discouraged from the use of Intergel®, especially during
intervention in which the gastrointestinal tract has been
opened, because the application of Intergel® may inter-
fered with the anastomotic wound healing process.
If surfaces are damaged, another way to prevent adhe-
sion formation is the application of phospholipids. Exper-
imental results have been effective using phospholipids,
mainly phospatidylcholine, both in models with peritoni-
tis and under normal conditions. No negative effects were
seen on wound healing or anastomosis safety [45,54].
However no clinical studies have been performed so far.
Polyethylene glycol has also been used as a barrier to
prevent post surgical adhesions. Experimental studies
showed good results and clinical trials reported an adhe-
sion-preventing effect in gynaecological surgery. Addi-
tionally, no effect has been noted on pregnancy rates after
treatment [54]. In contrast, a Meta-analysis failed to dem-
onstrate the evidence for the use of polyethylene glycol in
the prevention of post surgical adhesions [47].
Fibrin sealant are compounds of fibrinogen and throm-
bin. They have the advantage of decreasing bleeding and
increasing the production of plasminogen activator (PA)
and plasminogen activator inhibitor-1 (PAI) which may
be beneficial in the prevention of adhesions [55]. But
experimental results are diverging and no clinical data are
available [56,57].
Non-dissoluble membranes of expanded polytetrafluo-
roethylen (ePTFE) have been used successfully to reduce
adhesions. But these membranes are difficult to apply and
must be fixed in place usually with sutures. In addition
they are non biodegradable and should be removed at a
later time raising the possibility of damage and subse-
quent adhesion formation during this surgical episode
[2]. One clinical study has been conducted, showing a
reduction in postoperative adhesions [58]. But ePTFE is
not widely used as a barrier in surgery at present.
No clinical data are available for the use of collagen
films as a barrier but experiments reported an effect
against adhesion formations [59]. Transplantation of an
autologous mesothelial cell sheet has recently shown pos-
itive experimental results and offers also a new interest-
ing platform for future development.
None of these agents mentioned above have been
proven to be uniformly efficacious and safe under all sur-
gical conditions. Despite initial promising results in post-
operative adhesion prevention, none of them have
become a standard application. Therefore there is still the
need of a barrier that is safe and efficient in reducing the
incidence and the extent of surgical adhesion occurring
after general abdominal surgical procedures.
A-Part® Gel consists of PVA and CMC and shows no
cytotoxity, no allergenic reactions, no systemic toxicity
and no genotoxicity [13]. Physical properties such as vis-
cosity and adherence to the wound have also been tested
with good results [26].
In this study A-Part® Gel is used as a physical barrier
between the injured peritoneal surface to prevent post
surgical adhesions. Animal studies have shown high effi-
ciency in the prevention of adhesions [26,27,60,61].
Wound healing and anastomosis healing were not nega-
tively affected by the application of A-Part® Gel in these
animals.
To explore the efficacy of A-Part Gel® in reducing adhe-
sion in humans, adhesion to the abdominal wall will be
assessed by ultrasound examination. The gold standard of
evaluating adhesion formation by second look assess-
ment is only possible in surgical procedures that require a
planned re-operation. However, as this limitation would
reduce the amount of eligible patients this assessment is
not being chosen, especially as there would be no benefit
for the primary objective of this trial as a safety study.
Assessment of adhesion development will be done by
ultrasound examination. Sigel et al. as well as Steitz et al.
[62,63] described a technique for non-invasive ultra-
sound examination to detect and map abdominal adhe-
sions. The findings that identify abdominal wall
adhesions are based on the presence or restriction of
ultrasonically observed movement of abdominal viscera
in reference to abdominal wall. Sliding is the result of
forces applied by respiratory excursions or by manual bal-
lottement of the abdominal wall and is referred to as vis-
cera slide. In brief, examination of spontaneous visceral
slide with ultrasound scanning, provide information on
the presence or absence of adhesions. Normal and abnor-
mal visceral slide can be distinctly defined by simple mea-
surement of excursion distance. Restricted visceral slide
has been defined as reduced movement at a given point
on the abdominal wall during ultrasound scanning of
spontaneous visceral slide produced by regular and deep
respirations or during longitudinal and transverse scan-
ning of induced viscera slide produced by manual com-
p r es s i o n .  I t  is  s t r o n g l y  c o rr e la t ed  wi t h  t h e  p r e s e n c e  o f
abdominal adhesions as several authors confirm. Most
studies report a sensitivity of 90% and a specificity
between 86-93% [62-64]. The method has only minor
shortcomings in the lower third of the abdomen and may
not detected a long thin adhesion or adhesions to the
movable omentum, probably because this type of adhe-
sion would not cause a significant restriction of viscera
movement [65]. For assessment at the laparotomy scar
spontaneous visceral slide is the most sensitive indicator
of adhesions [62,63,66].
Conclusions
This prospective, randomised, controlled, patient - and
observer- blinded, single centre study evaluates as a pri-Lang et al. BMC Surgery 2010, 10:20
http://www.biomedcentral.com/1471-2482/10/20
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mary endpoint, if the application of A-Part® Gel is safe as
adhesion prophylaxis, in comparison to a non-treated
control group, during and after abdominal surgery.
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